<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89127">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022852</url>
  </required_header>
  <id_info>
    <org_study_id>HarbinMU-BCui-001</org_study_id>
    <nct_id>NCT02022852</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer</brief_title>
  <official_title>Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared curative effect，safety and compliance between concurrent chemoradiotherapy and
      chemo-chemoradio-chemo sequential therapy in locally advanced mid/low rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients were divided into two arms according to the defined conditions (pathology
      rectal adenocarcinoma；distal distance of tumor from anal verge &lt; 10cm；TNM staging
      T3-4N0-2；no distant metastasis；Karnofsky score≥70) in this prospective, single center, open,
      non randomized trail (arm A:concurrent chemoradiotherapy, arm B:sequential therapy).
      Regimens:Arm A:50Gy,2Gy/day per time, 5 days a week, for 5 weeks. +capecitabine 850mg/m2
      bid on the day accept radiotherapy. Rest for 8 weeks. Arm B: XELOX 2 cycles (oxaliplatin
      130mg/m2 ivgtt 2-6h day 1, capecitabine 1000 mg/m2 Bid day 1-14, repeat every 3 weeks ) →
      50Gy,2Gy/day per time, 5 days a week, for 5 weeks.+capecitabine 850mg/m2 bid on the day
      accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks. Evaluate pre chemotherapy, pre
      radiotherapy and pre surgery individually. Surgeries followed TME(total mesorectal excision)
      and PANP(pelvic autonomic nerve preservation) for patients in both arms. Take pathological
      evaluation of tumors. Take XELOX therapy till 6-8 cycles(pre and after surgery total).
      Follow up according the schedule.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3-year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants with Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.</description>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>XELOX 2 cycles (oxaliplatin 130mg/m2  ivgtt  2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.</description>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathology rectal adenocarcinoma

          -  Distal distance of tumor from anal verge &lt; 10cm

          -  TNM staging T3-4N0-2(MRI)

          -  No distant metastasis

          -  Karnofsky score≥70

          -  Female patients need contraception during the test

          -  Postmenopausal women for at least 12 months, expect pregnancy possibility

          -  Patients did not receive chemotherapy, radiotherapy in any form before

          -  No other severe related diseases (such as other tumor, severe cardiac and central
             nervous system diseases, etc.)

        Exclusion Criteria:

          -  Be treated by radiotherapy, chemotherapy or tumor biological therapy before

          -  Received immunosuppressive therapy (including corticosteroids)

          -  Participated in other clinical trial(s) in 1 month

          -  With malignant tumor of colon

          -  Peripheral neuropathy (WHO I level and above)

          -  Neurological or psychiatric abnormalities affecting cognition , including central
             nervous system metastasis

          -  Severe allergies or allergic history

          -  Severe pulmonary or heart disease

          -  Pregnant or lactation or refuse contraception during the test

          -  Suffering other malignant tumors in past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binbin Cui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Abdominal Surgery, Harbin Medical University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binbin Cui, MD</last_name>
    <phone>+86 13351112888</phone>
    <email>13351112888@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binbin Cui, MD</last_name>
      <phone>13351112888</phone>
      <email>13351112888@163.com</email>
    </contact>
    <investigator>
      <last_name>Binbin Cui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Binbin Cui</investigator_full_name>
    <investigator_title>Director of Abdominal Surgery Department</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <keyword>Sequential Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
